Clinical TrialJul 13, 2026, 07:22 AM
Q32 Bio Bempikibart SIGNAL-AA Trial Shows Positive 36-Week Results
AI Summary
Q32 Bio announced positive 36-week topline results from Part B of its SIGNAL-AA Phase 2a clinical trial for bempikibart in patients with severe or very severe alopecia areata. The trial showed a mean percent reduction in SALT score of 35.3% in the mITT analysis, with 40.0% of patients achieving a SALT-20 response. Bempikibart demonstrated a generally well-tolerated safety profile with no new safety signals. The company intends to advance bempikibart into a registration-directed program in the first half of 2027.
Key Highlights
- Mean percent reduction in SALT score from baseline of 35.3% in mITT analysis.
- 40.0% of mITT patients achieved SALT-20 response at Week 36.
- 44.0% of mITT patients achieved SALT30 response at Week 36.
- 44.0% of mITT patients achieved SALT50 response at Week 36.
- Bempikibart showed a generally well-tolerated safety profile with no new safety signals.
- No serious adverse events or Grade 3 or higher adverse events related to treatment.
- Company plans to advance bempikibart into a registration-directed program in H1 2027.
Price Impact
More from QTTB